skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: During the merger period in the Canadian Cannabis Industry, who do you see as the potential winners?
Read Answer Asked by Van on December 01, 2017
Q: Hello Peter and Ryan,
Cannimed has provided the following press release
http://www.businesswire.com/news/home/20171130006170/en/Actions-Words-Aurora-CEO%E2%80%99s-Actions-Reveal-Aurora
which basically illustrates insider selling by Aurora executives on November 28, 2017 while Aurora is in the midst of a takeover of Cannimed.
How is this recent information on insider selling obtained? I am thinking of adding to Savaria Corp giving it total of 5 percent weight and Knight to 7 percent given its recent weakness. Any comments please. Thanks again
Read Answer Asked by umedali on December 01, 2017
Q: You had responded to a previous member question about Neptune Tech waiting for its Investor communications on Nov 28th. I see it has sold the Krill Oil business and is now into cannabis derivative products. The current p/e is stated as 5.5 x and there was quite a bit of insider buying (albeit at lower prices). Has your opinion changed as to whether this would be a good speculative purchase for me?
Thanks,
Brian
Read Answer Asked by Brian on December 01, 2017
Q: Hello Folks:
Could you please give me your view on Merck and Company (which along with Smith- Kline) has had problems executing new drugs (eg. lung cancer medications) in their pipelines. I also have previously owned Gilead, whose new HIV drug was reduced in value because of government pricing restrictions. My other health care equities are Johnson and Johnson and Knight Therapeutics. Do you think there are better health industry options (with decent dividends and growth potential) in the U.S. other than companies such as Merck, Gilead etc. or should one look to another sector.
Thanks for everything
brian
Read Answer Asked by Brian on November 30, 2017
Q: Good afternoon 5i team,
I have been looking into tax loss buying and keep coming back to your high view of Knight Therapeutics. It seems that a good deal of your views on the stock depends upon management. And in looking into the stock a little, it does seem that Jonathan Goodman is a kind of Wayne Gretzky in the business world. A rich kit who did well:). Here in Montréal he also recognized as an important philanthropist. A couple questions I have that I would appreciate your seasoned view on:
The CFO left but he doesn't seem to be just any CFO. he was also it seems a kind of founding partner of Knight. His position has been taken by the former CF O of Paladin, so that is good. But, he does seem to have been more than a CFO. I notice that the company that he moved to has become increasingly closer to Knight. So, I was wondering whether this was perhaps a strategic move by both companies. But, perhaps I am reading too much into it. You probably have heard more about this change than I would have and so I would appreciate you view on both the loss and the possibility of a strategic move.

Secondly, it seems that Jonathan Goodman is all - important at GUD. He has had an accident and although he seems to be, as he says, 'Almost' as good as ever, there is still a question there. He seems to have the intelligence to find a small but lucrative niche in this field and has the strength and selling ability to make the most of it. He looks good. But, what if he goes? I am not sure but I believe you mentioned in your report that the actual cash that they hold would cushion against that eventuality. Am I right in that understanding?

And heck, since it is Black Friday, I will throw another question in for free: You say that patience is needed. He says that it is going to take twenty years. Many of us are beginning to see twenty years as a pretty big number and we may not be here to see the tree grow. So, is it a good investment for the older crew? But, maybe like the old apple tree, we are better to plant one for the next generation.
thanks
Read Answer Asked by joseph on November 27, 2017
Q: RE: Peter Lynchs' general positivity about spin offs.
Opinion about the new spin off Viemed from PHM. Do you know if any of the old management from PHM will be involved with the new company or will it be fresh people from outside rather then some reshuffling of the old mismanaging guard?
Do know how the arrangement will work wrt shares. I don't own any PHM at the moment. Would there be any benefit of purchasing any before the split?
Thanks
Read Answer Asked by JEFF on November 24, 2017
Q: Kudos to your new website, it’s very user friendly and a good tool for the small DIY investor!
My inquiry is on a Canadian Healthcare ETF (HHL) which I find interesting in that it includes US companies such as Novartis, Stryker, Medtronic, Johnson & Johnson and Anthem in the top 10 holdings, indicated dividend is north of 8.00%!
Also, if one is to hold it in a TFSA would the dividends be subject to the 15% foreign withholding tax?
Thnx for your great service!!
Read Answer Asked by David on November 22, 2017
Q: looking to buy some pharmaceutical stocks....can you please provide your 4 or 5 favs? or is there an ETF you would look at ? thank you...
Read Answer Asked by adam on November 22, 2017
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!